CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Erythropoiesis - Stimulating Agent codes

8 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 56.41M services · est. ▼ 24.0% YoY · 29,246 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 26.84M observed fee-for-service services

See the national market for Q0138 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 38.91M services · est. ▲ 4.3% YoY · 27,420 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 20.18M observed fee-for-service services

See the national market for J0881 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1756 Injection, iron sucrose, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 20.03M services · est. ▼ 23.5% YoY · 17,377 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9.66M observed fee-for-service services

See the national market for J1756 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 7.77M services · est. ▼ 15.3% YoY · 21,358 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.73M observed fee-for-service services

See the national market for J0885 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 3.13M services · est. ▼ 27.0% YoY · 10,415 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.56M observed fee-for-service services

See the national market for Q5106 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0896 Injection, luspatercept-aamt, 0.25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 596,970 services · est. · 188 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 301,368 observed fee-for-service services

See the national market for J0896 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1750 Injection, iron dextran, 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 336,167 services · est. ▲ 154.8% YoY · 7,843 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 169,520 observed fee-for-service services

See the national market for J1750 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1448 Injection, trilaciclib, 1mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 63,757 services · est. · 22 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 31,800 observed fee-for-service services

See the national market for J1448 → ranked groups · states · 12-yr trend